company background image
STVN

Stevanato Group NYSE:STVN Stock Report

Last Price

US$15.13

Market Cap

US$4.0b

7D

-3.5%

1Y

n/a

Updated

05 Jul, 2022

Data

Company Financials +
STVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

STVN Stock Overview

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare.

Stevanato Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stevanato Group
Historical stock prices
Current Share PriceUS$15.13
52 Week HighUS$29.18
52 Week LowUS$13.36
Beta0
1 Month Change-7.18%
3 Month Change-19.48%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-23.08%

Recent News & Updates

Shareholder Returns

STVNUS Life SciencesUS Market
7D-3.5%2.0%0.3%
1Yn/a-18.0%-18.4%

Return vs Industry: Insufficient data to determine how STVN performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how STVN performed against the US Market.

Price Volatility

Is STVN's price volatile compared to industry and market?
STVN volatility
STVN Average Weekly Movement7.6%
Life Sciences Industry Average Movement11.5%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: STVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: STVN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19494,652Franco Morohttps://www.stevanatogroup.com

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy.

Stevanato Group Fundamentals Summary

How do Stevanato Group's earnings and revenue compare to its market cap?
STVN fundamental statistics
Market Cap€3.91b
Earnings (TTM)€125.49m
Revenue (TTM)€863.15m

31.2x

P/E Ratio

4.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
STVN income statement (TTM)
Revenue€863.15m
Cost of Revenue€595.40m
Gross Profit€267.75m
Other Expenses€142.25m
Earnings€125.49m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.47
Gross Margin31.02%
Net Profit Margin14.54%
Debt/Equity Ratio25.8%

How did STVN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is STVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STVN?

Other financial metrics that can be useful for relative valuation.

STVN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.3x
Enterprise Value/EBITDA18.4x
PEG Ratio2.8x

Price to Earnings Ratio vs Peers

How does STVN's PE Ratio compare to its peers?

STVN PE Ratio vs Peers
The above table shows the PE ratio for STVN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.9x
MEDP Medpace Holdings
25.2x13.4%US$5.0b
ABCL AbCellera Biologics
14.4x-52.7%US$3.0b
SHC Sotera Health
41.1x25.9%US$5.5b
SYNH Syneos Health
31x19.8%US$7.5b
STVN Stevanato Group
31.2x11.0%US$4.0b

Price-To-Earnings vs Peers: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (27.9x).


Price to Earnings Ratio vs Industry

How does STVN's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the US Life Sciences industry average (30.3x)


Price to Earnings Ratio vs Fair Ratio

What is STVN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STVN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.2x
Fair PE Ratio24x

Price-To-Earnings vs Fair Ratio: STVN is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (24x).


Share Price vs Fair Value

What is the Fair Price of STVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: STVN ($15.13) is trading below our estimate of fair value ($33.58)

Significantly Below Fair Value: STVN is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: STVN is poor value based on its PEG Ratio (2.8x)


Discover undervalued companies

Future Growth

How is Stevanato Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STVN's forecast earnings growth (11% per year) is above the savings rate (1.9%).

Earnings vs Market: STVN's earnings (11% per year) are forecast to grow slower than the US market (12.8% per year).

High Growth Earnings: STVN's earnings are forecast to grow, but not significantly.

Revenue vs Market: STVN's revenue (8.7% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: STVN's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STVN's Return on Equity is forecast to be low in 3 years time (14.6%).


Discover growth companies

Past Performance

How has Stevanato Group performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


16.5%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: STVN has a high level of non-cash earnings.

Growing Profit Margin: STVN's current net profit margins (14.5%) are lower than last year (15%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if STVN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare STVN's past year earnings growth to its 5-year average.

Earnings vs Industry: STVN earnings growth over the past year (16.5%) underperformed the Life Sciences industry 21%.


Return on Equity

High ROE: STVN's Return on Equity (14.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Stevanato Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: STVN's short term assets (€866.4M) exceed its short term liabilities (€348.8M).

Long Term Liabilities: STVN's short term assets (€866.4M) exceed its long term liabilities (€234.1M).


Debt to Equity History and Analysis

Debt Level: STVN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if STVN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: STVN's debt is well covered by operating cash flow (58.1%).

Interest Coverage: STVN's interest payments on its debt are well covered by EBIT (40.1x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Stevanato Group current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.29%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate STVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STVN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: STVN is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as STVN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Franco Moro (59 yo)

3.5yrs

Tenure

Mr. Franco Moro has been Chief Executive Officer and Director of Stevanato Group S.p.A. since February 18, 2021 and as its Chief Operating Officer since 2019. He graduated in Chemical Engineering from the...


Leadership Team

Experienced Management: STVN's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: STVN's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: STVN only recently listed within the past 12 months.


Top Shareholders

Company Information

Stevanato Group S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Stevanato Group S.p.A.
  • Ticker: STVN
  • Exchange: NYSE
  • Founded: 1949
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$4.005b
  • Shares outstanding: 264.70m
  • Website: https://www.stevanatogroup.com

Number of Employees


Location

  • Stevanato Group S.p.A.
  • Via Molinella, 17
  • Piombino Dese
  • Padova
  • 35017
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/05 00:00
End of Day Share Price2022/07/05 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.